Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsCentene Ambetter formulary Coverage & Prior Auth |…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentCentenePolicy N/A

    Ambetter Health Formulary (Prescription Drug List) - Coverage Criteria

    Customize your policy alerts

    Sign up for all Centene policy alerts

    Know when Centene releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This document describes the Ambetter Health Formulary (prescription drug list), coverage tiers, formulary keys (PA, QL, AL, ST, NF, SP, SF), prior authorization processes, opioid new-start limits, and pharmacy-related fill requirements for members covered by Ambetter plans.

    Policy Summary
    PayerCentene
    PolicyAmbetter Health Formulary (Prescription Drug List) - Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateJan 1, 2025
    Next Review DateN/A
    Key ActionProviders must submit a Prior Authorization form for drugs marked PA and include supporting documentation when requesting coverage beyond listed quantity or new-start limits.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    Tier 0–4Formulary tiers described
    7-dayOpioid new-start limit
    QL presentQuantity limits present
    PA presentPrior authorization noted
    Tier 4Specialty handling

    Coverage and Utilization Controls

    Product-level coverage controls

    Coverage and utilization controls are applied per listed product and presentation; common controls include tier placement, quantity limits, age limits, prior authorization, specialty pharmacy and new-start supply caps.

    Formulary controls per product: Each product entry may include one or more: Tier assignment; QL (quantity limit) expressed per day, per fill, or per time period; AL (age limit); PA (prior authorization); SP (specialty pharmacy); max fills per X days; and new-start supply restrictions.See per-product QL entries (e.g., QL(280 ML per 56 day(s)), QL(3.6 ML per 28 day(s)))

    Interpret controls for the specific product presentation in the full formulary feed.

    General coverage with limits

    Coverage is provided on specified tiers with utilization controls that limit initial and ongoing dispensing.

    Standard formulary controls: Products are covered on their assigned formulary tier AND the following utilization controls apply where specified: new-start supply limits (commonly 7 days for opioid/analgesic products), quantity limits (QL) per day or per fill, and prior authorization (PA) or specialty (SP) requirements.
    Policy Summary
    PayerCentene
    PolicyAmbetter Health Formulary (Prescription Drug List) - Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateJan 1, 2025
    Next Review DateN/A
    Key ActionProviders must submit a Prior Authorization form for drugs marked PA and include supporting documentation when requesting coverage beyond listed quantity or new-start limits.
    SourceLink
    On This Page
    Coverage and Utilization ControlsCodes, Strengths, and Quantity ExamplesPrior Authorization, Step Therapy, and DocumentationFormulary Terms and AbbreviationsNew-Start and Starter Kit ControlsOngoing Therapy ControlsStep Therapy Flags and TablesQuantity Limits by ProductDispensing Site and Specialty Pharmacy Requirements
    New-start limits often = 7 day(s); see per-product QL values

    Examples: New starts limited to 7 day supply for many opioid presentations; QL examples shown on product lines.

    Formulary coverage logic

    Coverage is determined by formulary tier and utilization management flags; QL, PA, and SP annotations on each line govern access.

    Formulary entry rule: A drug is covered according to its assigned tier; where QL is specified the listed quantity limit applies; where PA or SP is indicated, prior authorization or specialty pharmacy processing is required before coverage is approved.Per-entry QL values (see product lines)

    Extracted from multiple formulary entries; check the specific line for exact values.

    Covered with Utilization Controls

    Coverage is provided with utilization management when specified; many high-cost or specialty agents require PA and/or SP and may have QLs.

    Formulary coverage with UM controls: Drug is on formulary at the listed tier AND any listed utilization controls (PA, SP, QL) must be satisfied when present.See per-drug QL (examples include QL(1 EA daily), QL(4 EA daily), QL(0.018 ML daily))

    Many antineoplastic and specialty agents show SP; PA; QL flags in the listing.

    Formulary tiering and utilization management

    Formulary coverage and utilization management are summarized below; tier assignment plus any PA/QL/SP designations determine access.

    Formulary rules summary: Medications are assigned tiers (e.g., 1A/1B/2/3/4) and may include Quantity Limits (QL) and Prior Authorization (PA) or Specialty Pharmacy (SP) designations. Coverage depends on tier and fulfillment of PA/step requirements where indicated.

    Examples: etravirine QL(2 EA daily); ribavirin QL(7 EA daily); epoprostenol/treprostinil entries flagged PA/SP.

    Formulary listing — flags only

    Formulary listing flags indicate coverage stance and any access requirements (PA, QL, SP) for each product entry.

    Formulary flags: Products are listed with Tier, PA, QL, and SP designations where applicable; these flags indicate required administrative or clinical steps for approval but do not contain detailed clinical PA criteria in this segment.

    Use PA/QL/SP flags to route requests to the applicable clinical or pharmacy prior authorization process.

    Coverage entries with tiering and utilization controls

    Selected formulary entries with tier assignments and explicit utilization controls are summarized as examples below.

    prednisone examples: Prednisone presentations appear with Tier = 1B; some formulations include AL(At least 12 yrs old) for pediatric access.

    See prednisone lines for specific AL annotations.

    clindamycin/benzoyl peroxide combinations: Clindamycin phosphate–benzoyl peroxide refrigerated and gel formulations show Tier = 1B, AL(At least 12 yrs old) on some lines, QL (e.g., 15 GM per 30 days) and PA indicated for certain presentations.QL(15 GM per 30 day(s)) for refrigerated formulation

    PA required for some formulations.

    biologic pens/syringes: Biologic pen and syringe products (e.g., COSENTYX, STELARA, SKYRIZI, TREMFYA, DUPIXENT) have tiering and explicit QL and PA flags noted on product lines.Examples include QL(0.025 ML daily); QL(60 GM per fill mail)

    PA indicated on multiple biologic presentations.

    Formulary coverage entries (partial)

    Partial formulary entries below illustrate how coverage is conditioned on dispensing within specified quantity limits and obtaining any required PA/ST/SP.

    SKYRIZI PEN example: SKYRIZI PEN entries list Tier = 1B with quantity limits such as QL(60 GM per fill mail) and max fill(s) per 30 days; PA is noted on some related lines.QL(60 GM per fill)

    chunks 234-235

    STELARA SOLN example: STELARA SOLN 45 MG/0.5ML listed with Tier = 1B and QL(0.012 ML) or QL(60 GM per fill mail) with max fill constraints; PA/ST annotations appear on related entries.QL(0.012 ML); QL(60 GM per fill)

    chunks 234-235

    Topical corticosteroids examples: Multiple topical corticosteroids (clobetasol, betamethasone, triamcinolone, mometasone, etc.) are listed with tiers (commonly 1B), QLs (e.g., QL 1–4 GM daily or mL values) and PA or ST flags for select formulations.varies by product (GM or mL)

    chunks 238-241

    Pediculicides & scabicides: Permethrin, ivermectin, crotamiton, malathion, spinosad are listed with tiers and in several entries PA is required for approved uses.PA for selected agents

    chunks 249-250

    Diagnostic products: Diagnostic/test-strip products (e.g., GLUCAGEN DIAGNOSTIC, THYROGEN) show QLs and note that non‑FDA uses require Prior Authorization; unit pack ranges are referenced for some products.Per-product QL or PA (e.g., THYROGEN ILimits: 1 max fill per 365 day(s))

    chunks 251-253

    The formulary is not intended to be an exhaustive list of all drugs covered under the prescription benefit. Not all dosage forms or strengths may be covered, and specific plan designs may further limit coverage for certain products or categories. The formulary is periodically reviewed and updated and may change over time; providers and staff should verify coverage, available presentations, and any associated utilization controls for the member’s specific plan prior to dispensing.

    This segment of the formulary extract does not include any explicit clinical exclusion criteria. Coverage entries are presented as product-level lines with tier designations and utilization controls (e.g., QL, AL, PA), but the text does not state specific conditions or diagnoses that would categorically exclude members from coverage.

    No explicit exclusion statements are given in these chunks. The listing provides tiering and utilization controls (quantity limits and occasional PA) for individual product presentations rather than broad clinical exclusions.

    This excerpt does not contain explicit coverage exclusions. Entries focus on tier assignment and quantity limits for specific products rather than identifying categories or clinical situations that are universally excluded.

    The segment emphasizes utilization management controls for listed agents (e.g., QL, SP, PA) and does not set out explicit exclusionary rules. Coverage is presented per product line with UM flags rather than as clinical exclusions.

    No explicit exclusion statements are present in these chunks; the entries describe tiering, quantity limits, and prior authorization requirements for individual drugs rather than listing clinical exclusions.

    This document segment does not state explicit exclusions. It provides formulary tier assignments and utilization controls per listed product without naming conditions or member groups that would be excluded from coverage.

    No explicit clinical exclusion criteria are listed in this excerpt. Product lines show tier, age limits, QL, ST, and PA flags for specific formulations; exclusionary language is not present here.

    Within the available extract there are no statements that designate products as "not medically necessary." Formulary lines instead report tier placement and utilization controls (e.g., QL, AL, PA) for each presentation; formal NMN language does not appear in this segment.

    These chunks do not contain explicit 'Not Medically Necessary' (NMN) findings. The entries focus on new-start supply limits and quantity limits for opioid/analgesic presentations rather than NMN determinations.

    No 'not medically necessary' statements are included in this excerpt. Information is limited to tiering and quantity-limit details for listed products.

    The provided chunks do not include explicit NMN language. Entries shown apply utilization controls (PA, QL) and specialty designations without identifying products as not medically necessary.

    No explicit 'Not Medically Necessary' wording appears in these chunks. The formulary lines describe tiers and QL values for antiviral and antiretroviral products and note PA/SP where applicable, without NMN declarations.

    These excerpts do not contain statements that services or products are 'not medically necessary.' Instead, entries identify PA and SP requirements for pulmonary hypertension starter/refill kits and related products.

    The extract does not include explicit 'not medically necessary' statements. Coverage language is presented as product-specific tiering and utilization management controls such as PA, QL, AL, and ST.

    Non‑FDA approved uses of certain diagnostic products require Prior Authorization and may be denied if a PA is not obtained. Providers should submit the required prior authorization documentation for off‑label diagnostic uses; failure to obtain PA may lead to denial of coverage for those non‑FDA indications.

    Codes, Strengths, and Quantity Examples

    Listed drug presentationsmixed
    NDC-like/unit descriptors presentDrug presentations and strengths are given (e.g., methylphenidate hcl TB24 18 MG, 27 MG; fentanyl PT72 12 MCG/HR, 25 MCG/HR, etc.) but no explicit NDC codes listed in this segment.
    NDC/CPT/other codesmixed
    No codes listed
    Formulation strengths listedNDC
    2.5 MG/0.5MLfondaparinux sodium 2.5 MG/O.SML (formulation/strength as listed)
    10 MG/0.8MLfondaparinux sodium 10 MG/O.8ML (formulation/strength as listed)
    5 MG/0.4MLfondaparinux sodium 5 MG/O.4ML (formulation/strength as listed)
    Enoxaparin strengthsNDC
    300 MG/3MLenoxaparin sodium SOLN IJ 300 MG/3ML
    30 MG/0.3MLenoxaparin sodium SOSY 30 MG/O.3ML
    40 MG/0.4MLenoxaparin sodium SOSY 40 MG/O.4ML
    Formulary entries (no billing codes)mixed
    no explicit CPT/HCPCS/ICD codesThis segment does not list procedure or diagnosis codes; it lists drug names, tiers, and utilization controls.
    No billing codes present in these chunksmixed
    No codes listed
    Documented quantity limits and fill constraintsmixed
    QL(2 EA daily)Quantity limit example listed for bosentan 125 mg and other items
    QL(4 EA daily)Quantity limit example listed for bosentan TBSO 32 MG
    max fill(s _ perl 180 dayls)Max fill example for UPTRAVI TITRATION TBPK
    No explicit billing codes in excerptmixed
    No codes listed
    Formulary unit pack codes / unit rangesNDC
    252600 UNIT-189600 UNIT-60000 UNITZENPEP CPEP (unit ranges) referenced as unit ranges for several products
    105000 UNIT-79000 UNIT-25000 UNIT-14000 UNIT-10000 UNIT-3000 UNITUnit ranges referenced for diagnostic/enzymes products
    Quantity limits examples — sample QL syntaxes and new-start limits
    Sample QL syntax (mL/EA/day)QL(0.072 EA daily); QL(3.6 ML per 28 day(s)); QL(280 ML per 56 day(s))
    New-start limit (opioids/analgesics)New starts limited to 7 day supply
    Package / period syntaxpackage(s) per 180 day(s); max fill(s) per 180 day(s)
    Starter kit syntaxmax fill(s) per 180 day(s) retail; 1 max fill(s) per 180 day(s) mail
    New-start supply — 7 day new-start limit example
    New-start supply exampleNew starts limited to 7 day supply
    Associated QL when limiting new startsQL(500 ML per fill retail) — shown alongside new-start limit in opioid entries
    Claim/documentation notePrescribers should expect documentation to support requests exceeding new-start supply
    Example QL per day — per-day QL examples (2/4/6 EA daily)
    Per-day unit examplesQL(2 EA daily); QL(4 EA daily); QL(6 EA daily)
    Per-day ML exampleQL(0.34 EA daily) listed for fentanyl PT72 formulations
    Per-day variants across opioidsSome entries combine new-start 7-day restriction with per-day QLs (e.g., QL(6 EA daily))
    example daily QL — e.g., QL(0.036 ML daily) for injectables
    Injectable per-day ML exampleQL(0.036 ML daily) — example shown for FASENRA SOSY
    Other injectable ML QLsQL(0.1073 ML) and QL(0.0144 ML daily) shown for NUCALA variants
    Package-per-period for injectablesQL(3.6 ML per 28 day(s) retail); QL(4 ML per 28 day(s) mail)
    Quantity limits examples — assorted QL examples (40 ML daily, 2 EA daily, etc.)
    Assorted QL examples (ML/EA)QL(40 ML daily); QL(60 ML); QL(6 EA daily); QL(2 EA daily); QL(8 EA daily)
    Per-period QL exampleQL(280 ML per 56 day(s))
    Large-pack QL exampleQL(60 GM per fill mail) for select biologic pens (SKYRIZI)
    Quantity Limits examples — per-agent/day examples
    Per-agent/day examplesQL(1 EA daily); QL(2 EA daily); QL(4 EA daily); QL(8 EA daily)
    Antineoplastic per-day QL examplesQL(0.143 ML daily); QL(0.018 ML daily) for select biologics/antineoplastics
    SP/PA flag noteMany entries include SP and PA alongside QL — documentation required for PA requests
    Oseltamivir per-fill limit — 10 EA per fill retail/mail and 1 fill per 90 days
    Oseltamivir per-fill limitQL(10 EA per fill retail; 10 per fill mail); limit 1 fill every 90 days
    Suspension per-fill exampleQL(125 ML per fill retail) for oseltamivir suspension with 1 fill every 90 days
    Claim/fill periodicity noteMax fill(s) per 90 day(s) indicated for oral influenza agents
    Age limit example — At least 12 yrs old for some products
    Age-limit exampleAL(At least 12 yrs old) — shown for multiple topical and prednisone formulations
    Topical age constraintsSeveral topical acne/antibacterial agents list AL(At least 12 yrs old)
    Documentation implicationAge limits must be respected on claims and during PA submissions
    Examples of quantity and fill thresholds — QL and max-fill examples
    Quantity and fill threshold examplesQL(3 GM daily); 2 max fill(s) per 30 day(s) retail; QL(60 GM per fill mail)
    Topical QL and max fill examplesQL(1 GM daily) and 15 GM per 30 day(s) retail for some clindamycin-benzoyl peroxide formulations
    Biologic pen fill limitsSKYRIZI/STELARA examples: 1 max fill per 30 days retail/mail; QL per fill specified
    Example quantity limits — grams, mL, units examples
    Quantity units examplesQL expressed in grams (GM), milliliters (ML), or units/each (EA) — e.g., QL(3 GM daily), QL(0.018 ML daily), QL(4 EA daily)
    Per-fill gram exampleQL(60 GM per fill mail) for select biologic pens (SKYRIZI/STELARA)
    Diagnostic QL exampleGLUCAGEN DIAGNOSTIC QL(0.035 EA daily) noted for diagnostic uses

    Prior Authorization, Step Therapy, and Documentation

    Prior Authorization

    Prior Authorization Required

    Prior Authorization Required: Many products listed across the formulary require prior authorization (PA). This includes selected opioid products (high‑strength, extended‑release, or specific formulations), numerous biologics and specialty injectables (for example NUCALA, XOLAIR, STELARA, TREMFYA, DUPIXENT, enoxaparin preparations), multiple antineoplastic agents (including targeted and hormonal therapies and many specialty oncology agents), selected antivirals (e.g., SOFOSBUVIR‑VELPATASVIR, SOVALDI), pulmonary hypertension therapies (epoprostenol, treprostinil, TYVASO kits, bosentan, OPSUMIT, TRACLEER), topical/ectoparasiticide agents (for example clindamycin‑benzoyl peroxide combos, spinosad, permethrin, malathion), and many other listed specialty or high‑cost agents. PA is also noted broadly for diagnostic and non‑FDA uses.

    • Providers must submit the payer Prior Authorization form with clinical rationale and supporting documentation.
    • Urgent PA requests: response within 24 hours of receipt of all necessary information; non‑urgent: within 72 hours (or faster if state law requires).
    • Denials will include specific reasons; incomplete requests will identify missing material information needed to complete the request.
    • Drugs flagged with PA, SP, or QL on the formulary may be denied at claim adjudication if PA or specialty enrollment is not obtained.
    • PA triggers include high‑strength/ER opioid formulations, specialty biologics, oncology agents, certain antivirals, pulmonary hypertension meds, and non‑FDA or diagnostic uses.
    • Some products show PA together with SP (specialty) indicating additional handling or fill constraints; others combine PA with QL (quantity limits) or ST (step therapy).
    • For many opioids new‑start supply limits apply (commonly limited to a 7‑day supply); PA may be required for higher strengths or certain formulations.
    • Topical agents and ectoparasiticides may carry QL, ST, or PA (examples: clindamycin‑benzoyl peroxide combos, clobetasol formulations, spinosad, permethrin, malathion).
    • Antineoplastic agents frequently require PA and may also be SP and/or QL; include drug name, dose, and indication on the PA request.
    • Non‑FDA or off‑label diagnostic uses require PA and may be denied without it.
    Denial Risk

    Quantity Limits, Step Therapy, and Denial Risk

    Quantity limits, step therapy, and PA interactions: exceedance of quantity limits (QL) or failure to follow step therapy (ST) or to obtain required PA may result in claim denial. Many formulary entries combine QL, PA and ST flags; providers should verify and document adherence to these rules before claim submission.

    • Some formulations include explicit QLs and max‑fill limits (examples: SOLU‑CORTEF 2 max fills per 30 days; various injectables with ML or dose‑based QLs).
    • Step therapy may apply to selected anticonvulsants and topical products — where ST is indicated, preferred agents must be tried first or PA must justify bypassing ST.
    • Step edits are sometimes implied by tiering and PA/SP flags even when explicit ST sequences are not listed.
    • New‑start opioid supplies are commonly limited (e.g., 7‑day supply) — prescribing above the new‑start limit may require PA and additional documentation.
    Documentation Required

    Documentation Required for Prior Authorization, Step Therapy, and Quantity Limit Exceptions

    Documentation requirements for PA, SP, QL, and ST: When submitting a prior authorization or requests to override QL or ST, provide clear clinical rationale and supporting medical records. For specialty drugs, include details on specialty enrollment, site of care if relevant, and dosing schedule. Document dosing and package/ML calculations when QL or SP settings are present.

    • Include diagnosis, prior therapy and response, contraindications/intolerance to preferred therapies (for ST exceptions), and proposed dosing with duration.
    • For antineoplastic agents, specify the exact drug, dose, regimen, and indication on the PA request.
    • Specialty drug (SP) requests should include specialty pharmacy information and any enrollment/dispensing site requirements.
    • When requesting overrides of QL, document why the clinical need exceeds the published quantity limit (include calculation of total dose, frequency, and intended duration).
    • Maintain copies of all submitted PA forms and supporting clinical records; denials for missing documentation will cite the missing information.
    Billing Rule

    Provider Actions — How to Submit and What to Expect

    Operational steps for providers: verify formulary flags (PA, SP, QL, ST) before prescribing; complete and submit the PA form with supporting documentation; track PA response timelines; and ensure specialty enrollment or site‑of‑care approvals as required.

    • Check the formulary entry for PA and QL flags at the time of prescribing — many formulary items require PA.
    • If PA is required, complete the payer’s PA form and submit all requested clinical documentation to avoid delays or denials.
    • Allow for urgent (24‑hour) and non‑urgent (72‑hour) PA response windows; follow up if the decision is not communicated within these timeframes.
    • If a product is SP flagged, coordinate with the specialty pharmacy and confirm any kit/refill restrictions (examples: TYVASO kits, starter/refill kit requirements).
    • For non‑FDA or off‑label diagnostic uses, obtain PA before performing or dispensing.
    Documentation Required

    Preventing Denials — Practical Documentation Tips

    When PA is indicated on the formulary, include explicit notes about QL, SP, and ST settings to prevent denials. Failure to document QL calculations, specialty handling, or step‑therapy rationale is a common reason for disapproval.

    • Document specific quantity calculations (e.g., mL per 28 days, units per day) when QLs are listed.
    • If a drug is both SP and PA, confirm specialty pharmacy enrollment and include that documentation with the PA form.
    • For ST entries that are not fully specified in the formulary, include documentation of prior therapies tried and outcomes to support exceptions.
    • Be aware that some agents list PA with package‑ or fill‑based limits (for example packages per 180 days); include dispensing plan to align with those limits.

    Formulary Terms and Abbreviations

    Formulary tiers and abbreviations — Tier 0–4 definitions and tier mapping
    Tier definitions (Tier 0–4)Tier 0 (preventive/no copay); Tier 1A/1B (lowest copayment); Tier 2 (preferred brand); Tier 3 (higher copayment); Tier 4 (specialty/highest copayment)
    Common formulary abbreviationsPA = Prior Authorization; QL = Quantity Limit; AL = Age Limit; ST = Step Therapy; SP = Specialty Pharmacy; NF = Non‑formulary; SF = Split Fill
    Specialty (Tier 4) noteSpecialty drugs may require fulfillment at participating specialty or hemophilia network pharmacies
    QL — Quantity Limit definition and examples
    Quantity Limit (QL) — definitionMaximum quantity or frequency allowed (examples: ML/day, EA daily, package(s) per X days).
    QL syntax examplesExamples in document: QL(0.072 EA daily); QL(3.6 ML per 28 day(s)); QL(280 ML per 56 day(s))
    QL applicationApplied per listed product/presentation; may be per day, per fill, or per period (e.g., 180 days)
    PA — Prior Authorization definition
    Prior Authorization (PA) — definitionApproval required from the plan before coverage for products marked PA; providers must submit the Prior Authorization form
    PA presence in listingPA is indicated alongside many biologic and specialty entries and may trigger denial if not obtained
    Response timelinesPrior Authorization responses occur within 24 hours for urgent requests and 72 hours for non‑urgent requests (unless state law is faster)
    AL — Age Limit definition
    AL — Age Limit definitionSpecifies minimum (or age range) required for coverage (e.g., 'AL(At least 12 yrs old)')
    Typical useApplied to topical agents and some oral formulations; must be observed on claims and PA submissions
    Example entryAL(At least 12 yrs old) shown for clindamycin-benzoyl peroxide and prednisone entries
    SP — Specialty Pharmacy designation
    SP — Specialty Pharmacy designationIndicates specialty dispensing/handling requirement; may require specialty pharmacy fulfillment and enrollment
    ConsequencesProducts marked SP often require PA and specific fulfillment sites (infusion center, home, or participating specialty pharmacies)
    Example entriesMany biologics (e.g., HUMIRA, ACTEMRA, STELARA, SKYRIZI) include SP flags and package limits per 180 days
    New-start supply limit — definition and example of 7-day new-start limit
    New-start supply limit — definitionRestriction that limits quantity dispensed for new therapy initiations (commonly shown as 'New starts limited to 7 day supply')
    Opioid new-start policyNew starts for certain analgesics/opioids are limited to a 7‑day supply; exceeding requires PA
    Operational notePrescribers should document clinical rationale when requesting greater than the listed new-start supply
    QL (Quantity Limit) — additional definition and examples
    QL — additional definitionMaximum permitted quantity per day or per fill as noted (examples: QL(2 EA daily), QL(180 ML daily), QL(60 GM per fill))
    Forms of QLExpressed as EA (each), ML, GM, package(s) per X days, or max fills per period
    Example usagesUsed across biologics, topical agents, injectables, and oral medications with per‑day or per‑period caps
    QL example — e.g., QL(0.036 ML daily)
    QL example (injectable mL/day)QL(0.036 ML daily) — example listed for FASENRA SOSY
    Biologic QL examplesQL(0.025 ML daily); QL(0.072 ML daily); QL(0.012 ML) — variants across biologic injectables
    Per‑fill gram exampleQL(60 GM per fill mail) for SKYRIZI/STELARA pen presentations
    PA — reiteration of prior authorization meaning
    PA — reiterationPA indicates prior authorization is required before coverage is approved for products marked PA
    Provider actionProviders must submit PA form; failure to obtain PA may lead to denial
    PA on biologics/specialtyMany starter kits and specialty entries include PA flags; check the formulary line for requirements
    SP — Specialty definition
    SP — specialty definition (restate)SP denotes specialty pharmacy designation, implying specialty handling, fulfillment, or site-of-care requirements
    ExamplesACTEMRA, HUMIRA, many antineoplastic and biologic injectables are flagged SP in the listing
    Implication for claimsSP entries often require specific dispensing channels and documentation at submission
    Quantity Limit shorthand (QL)
    Quantity Limit shorthandQL — used to denote quantity limits in listing (e.g., QL(2 EA daily))
    Common placementsPlaced in ILimits/Drug Requirements fields per product line to control day/fill/period quantities
    InterpretationMust be interpreted per product presentation and unit of measure (EA/ML/GM) shown
    Prior Authorization shorthand (PA)
    Prior Authorization shorthandPA — abbreviation used on formulary to indicate prior authorization required
    Where seenAppears next to many branded biologic, specialty, and high‑cost product lines
    Provider expectationSupporting clinical documentation typically required when submitting PA
    Step Therapy shorthand (ST)
    Step Therapy shorthandST — indicates a step therapy requirement (try preferred drugs first) when present
    Common useApplied to select topical agents and some anticonvulsants as noted in the listing
    Absence noteExplicit step sequences are not provided in this segment; follow formulary-listed ST annotations
    Prior Authorization (PA) definition (antineoplastic context)
    PA (antineoplastic context)PA indicates prior authorization required for many antineoplastic agents in the listing; requests should document drug, dose, and indication
    SP/QL in antineoplasticsAntineoplastic entries often combine SP and QL with PA — follow specialty/PA processes
    ExamplesMultiple antineoplastic agents list QL per day and PA flags (see antineoplastic segments)
    Quantity Limit (QL) definition (antineoplastic context)
    QL (antineoplastic/biologic)Quantity Limit defines max amount allowed per day/fill for injectables and antineoplastics (examples: QL(0.143 ML daily); QL(0.025 ML daily))
    SP implicationMany of these agents also require specialty dispensing (SP) and PA
    Per-fill gram examplesQL(60 GM per fill mail) for certain pen presentations
    Specialty Pharmacy requirement (SP)
    Specialty Pharmacy requirement (SP)SP denotes specialty pharmacy handling; specialty drugs may have special fill/handling and network requirements
    DocumentationPA and SP flagged products require documentation and specialty fulfillment per listing
    Site-of-care noteSome SP items are limited to infusion centers or specific specialty pharmacies
    QL — Quantity Limit definition example
    QL examples (biologics/injectables)QL(0.025 ML daily); QL(0.072 ML daily); QL(0.012 ML) — per‑day ML limits for biologic injectables
    Per-fill mass exampleQL(60 GM per fill mail) for SKYRIZI/STELARA pen presentations
    Associated PA/SPThese QLs frequently appear alongside PA and SP flags in the listing
    PA / SP definition — combined explanation
    PA/SP combined explanationPA = prior authorization required; SP = specialty pharmacy designation — entries may show both, requiring PA and specialty fulfillment before coverage
    Operational impactClaims for products with PA/SP flags may be denied without required approvals or specialty enrollment
    ExamplesPulmonary hypertension and biologic injectables frequently show PA;SP in the listing
    Tier 1B — notation of tier label presence
    Tier 1B presenceTier 1B appears throughout the listing for many topicals and select injectables (notation present in formulary)
    MeaningTier labels indicate copayment level and help route utilization controls (QL/PA/ST) when present
    Example productsSKYRIZI, STELARA, topical corticosteroids frequently appear with Tier 1B
    PA — Prior Authorization reiteration
    PA reiterationPA indicates prior authorization is required for the product before coverage will be approved
    Provider expectationProvide clinical documentation as required for PA; missing PA can trigger claim denial
    Where shownAppears on topical, biologic, and specialty product lines as annotated in ILimits/Drug Requirements
    AL — Age limit example entries
    AL example entriesAL(At least 12 yrs old) used for prednisone and multiple topical formulations
    Topical/dermatologic age rulesSeveral acne and topical antifungal/antibacterial agents include AL(At least 12 yrs old)
    Claims noteAge limits must be applied at dispensing and during PA review
    QL — Quantity limit examples and examples
    QL examples and explanationQuantity limits vary by product and unit (e.g., QL(3 GM daily), QL(4 GM daily), QL(60 GM per fill), QL(0.018 ML daily))
    Per-product applicationEach QL applies to the specific product/presentation listed on the formulary line
    EnforcementClaims exceeding listed QL may be denied or require PA/documentation
    PA — Prior Authorization definition
    PA definition (concise)Prior Authorization (PA) — approval required before coverage is authorized for certain products
    How to requestProviders must complete prior authorization forms and supply required documentation per formulary instructions
    Denial riskMissing or insufficient PA documentation may result in denial with explanation of missing information
    QL (Quantity Limit) — additional examples
    Per-product QL (examples)QL may be specified in GM, ML, or EA per product — e.g., QL(3 GM daily); QL(0.025 ML daily); QL(6 EA daily)
    Max-fill per periodSome products show max fills per 30/90/180 days (e.g., 1 max fill per 30 days retail/mail; 1 max fill per 90 days)
    Documentation requirementPA and QL settings should be included in authorization submissions where applicable
    PA — Prior Authorization shorthand
    PA shorthandPA — Prior Authorization; marked on formulary entries to require plan approval prior to coverage
    Provider actionSubmit PA form and supporting documentation; follow plan PA timelines (24/72 hours) as applicable
    ConsequencesFailure to obtain PA may result in denial with a clear explanation of missing information
    ST — Step Therapy shorthand (ST)
    ST shorthandST — Step Therapy; indicates trying specified preferred drugs first when present
    Where appliedNoted for selected topical agents and some anticonvulsants in the listing (e.g., clindamycin phosphate‑tretinoin)
    GuidanceFollow formulary ST annotations; explicit sequences not provided in this segment

    New-Start and Starter Kit Controls

    New-start limits

    New-start supply restrictions apply to selected analgesics and opioid products to limit initial dispensing.

    New-start supply restriction (opioids/analgesics): Certain analgesic and opioid presentations are limited to a 7-day supply for new therapy starts.7 day(s)

    Document shows 'New starts limited to 7 day supply' on multiple opioid/analgesic entries (e.g., butalbital combinations, morphine, oxycodone, hydrocodone).

    New-start limits

    Summary of initial therapy restrictions appearing across opioid/analgesic entries.

    New-start opioid limits: Many opioid products are restricted for new starts to a 7-day supply; quantity limits (QL) and PA may also apply for particular strengths or formulations.7 day(s)

    Examples: morphine, oxycodone, hydrocodone entries reference 7-day new-start limits; some lines also list QL per day and PA.

    Initial therapy rules for biologics/specialty

    Some biologic injectables and specialty products require prior authorization and have product-specific quantity limits for initial dispensing.

    Biologic/specialty initial coverage: Biologic injectables (examples: NUCALA, FASENRA, XOLAIR) are listed with QL values and PA indicators; prior authorization must be obtained for initial coverage when PA is indicated.Per-product QL (e.g., FASENRA QL(0.036 ML daily); NUCALA QL values shown)

    See biologic lines for exact mL or unit-based QLs and PA requirements.

    Initial coverage notes

    Formulary placement and utilization flags influence initial access; some products note step-therapy or documentation requirements for initiation.

    Formulary controls for initial prescribing: Initial dispensing is governed by tier assignment and utilization controls (QL, PA, ST). Where 'ST' is present, try preferred agents first per formulary; documentation may be required for PA/ST requests.

    Examples: select anticonvulsants and topical agents show ST; EPIDIOLEX and others show PA.

    Antiviral initial therapy notes

    Selected antiviral entries include quantity limits and prior authorization requirements for initial therapy.

    SOFOSBUVIR-VELPATASVIR initial coverage: SOFOSBUVIR‑VELPATASVIR is listed with Tier = 1B and ILimits including QL(1 EA daily) and PA required for coverage.QL(1 EA daily)

    Refer to antiviral formulary lines for PA submission requirements.

    Starter kit listing

    Starter and refill kits for specialty products are listed with PA or SP designations.

    Starter/refill kit controls: TYVASO STARTER KIT and TYVASO REFILL KIT entries are present and flagged PA; kits and associated starter/refill presentations require prior authorization as indicated.

    Specific clinical initiation criteria are not provided in this segment; see full PA criteria for details.

    Step therapy / initial trial

    Some topical products are subject to step therapy or require trial of preferred formulations before coverage is approved.

    Topical step/initial trial: Entries annotated 'ST' (step therapy) indicate that preferred topical agents or formulations should be tried prior to coverage of the listed product (examples include clobetasol FOAM/GEL entries).

    Refer to the formulary line for 'ST' annotation to determine applicable preferred agents.

    Ongoing Therapy Controls

    Continuation therapy limits

    Continuation or ongoing therapy is managed by per-product quantity limits and fill constraints.

    Continuation limits: Ongoing therapy is subject to the listed QLs and max fill constraints per product (e.g., daily QLs or per‑fill limits). Requests to exceed these limits require prior authorization with supporting documentation.See per-product QL entries (examples: QL(2 EA daily), QL(180 ML daily))

    Continuation specifics vary by product and are not uniformly listed in this segment.

    Step Therapy Flags and Tables

    Product / exampleStep therapy (ST) indicated?Notes (tier, QL, PA)
    Various stimulant formulations (e.g., methylphenidate presentations)
    covered with ST flags on select presentations
    Tiers vary (1B–4); QL examples include QL(280 ML per 56 days), QL(1 EA daily) in listings; see formulary lines for specific presentation-level ST indication (some stimulants listed with ST).
    Product / exampleStep therapy (ST) indicated?Notes (tier, QL, PA)
    fenoprofen calcium TABS
    ST
    Listed Tier = 1B; ILimits include QL(4 EA daily); ST annotation present on formulary line (fenoprofen calcium TABS).
    Product / exampleStep therapy (ST) indicated?Notes (tier, QL, PA)
    Buprenorphine-containing formulations (films, sublingual, sublingual tablets)
    No explicit step sequence in these chunks
    Tier commonly 1B; quantity limits listed (e.g., QL(2 EA daily), other QLs) but no ST algorithm documented in these excerpts; PA not routinely shown here.
    Product / exampleStep therapy (ST) indicated?Notes (tier, QL, PA/SP)
    Antiarrhythmics / related agents (e.g., propafenone, flecainide)
    No explicit ST sequences in excerpt
    Tier assignments shown (often 1B); QL examples include QL(15 ML daily) for propafenone; PA/SP flags are the primary controls in listings.
    Product / exampleStep therapy (ST) indicated?Notes (tier, QL, PA)
    Selected anticonvulsants (e.g., APTIOM (lacosamide), eslicarbazepine acetate)
    ST flagged on some entries
    Examples: APTIOM listed with QL(2 EA daily) and ST; eslicarbazepine acetate listed with QL(2 EA daily) and ST. Specific step algorithms not provided in the excerpt.
    Product / exampleStep therapy (ST) indicated?Notes (primary access control)
    Loop diuretics and related (e.g., furosemide, bumetanide)
    ST text absent
    Primary controls shown are SP and PA (e.g., furosemide SOLN PO flagged SP; bumetanide TABS flagged SP; PA required where indicated).
    Product / exampleStep therapy (ST) indicated?Notes (tier, PA/SP implication)
    Pulmonary hypertension agents (e.g., sildenafil PH formulations, bosentan)
    Explicit ST sequences not provided (tiering and PA/SP may imply preferred sequence)
    Some entries list Tier = 1B (sildenafil PH) and PA/SP flags; bosentan entries show QL(2 EA daily) and PA/SP — these tier/PA/SP settings may imply sequencing though no explicit steps listed.
    Product / exampleStep therapy (ST) indicated?Notes
    Pulmonary Hypertension Phosphodiesterase class (example: sildenafil PH formulations)
    No explicit ST rules; Tier 1B noted (preference implication)
    Tier = 1B appears for pulmonary hypertension phosphodiesterase presentations — tiering suggests preferred agents but explicit ST criteria are not provided in this segment.
    Product / exampleStep therapy (ST) indicated?Notes (tier, QL, PA)
    Clindamycin phosphate — tretinoin combinations and related topical acne agents
    ST indicated on selected topical entries
    Examples: clindamycin phosphate- tretinoin listed Tier = 1B with QL(6 GM daily); some tretinoin and acne lotion entries show AL(At least 12 yrs) and ST annotations — step edits apply to selected topical agents.
    Product / exampleStep therapy (ST) indicated?Notes
    Clobetasol propionate topical formulations (foam, gel, ointment, solution)
    ST annotated on some formulations
    Examples: clobetasol propionate FOAM and GEL entries show ST and QLs (e.g., QL(3 GM daily) for foam; gel QL(2 GM daily)); formulary notes advise following the preferred sequence when ST present.
    Product / exampleSpecialty dispensing (SP) or Prior Authorization (PA)?Notes
    TYVASO starter/refill kits; treprostinil; epoprostenol
    SP; PA indicated
    Entries for TYVASO, treprostinil, epoprostenol are flagged SP and PA — specialty dispensing and prior authorization are primary access controls in these listings.

    Quantity Limits by Product

    Dispensing Site and Specialty Pharmacy Requirements

    Note
    Note
    Note
    Note